Dan Leonard
Stock Analyst at UBS
(2.44)
# 2,199
Out of 4,829 analysts
287
Total ratings
52.2%
Success rate
-6.58%
Average return
Main Sectors:
Stocks Rated by Dan Leonard
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TECH Bio-Techne | Maintains: Buy | $95 → $70 | $53.90 | +29.87% | 11 | May 9, 2025 | |
| BRKR Bruker | Maintains: Neutral | $57 → $45 | $40.26 | +11.77% | 11 | May 8, 2025 | |
| IQV IQVIA Holdings | Maintains: Buy | $255 → $185 | $156.13 | +18.49% | 14 | May 7, 2025 | |
| BIO Bio-Rad Laboratories | Maintains: Buy | $355 → $310 | $256.68 | +20.77% | 20 | May 2, 2025 | |
| BIO.B Bio-Rad Laboratories | Maintains: Buy | $355 → $310 | $252.64 | +22.71% | 20 | May 2, 2025 | |
| GH Guardant Health | Maintains: Buy | $65 → $70 | $41.66 | +68.03% | 9 | May 1, 2025 | |
| RVTY Revvity | Upgrades: Buy | $145 → $115 | $98.50 | +16.75% | 2 | May 1, 2025 | |
| TMO Thermo Fisher Scientific | Maintains: Buy | $715 → $500 | $432.59 | +15.58% | 15 | Apr 24, 2025 | |
| DHR Danaher | Maintains: Buy | $275 → $240 | $200.83 | +19.50% | 17 | Apr 23, 2025 | |
| TXG 10x Genomics | Maintains: Neutral | $20 → $14 | $9.49 | +47.52% | 4 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $29 → $25 | $13.00 | +92.31% | 7 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $250 → $185 | $143.08 | +29.30% | 6 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $7 → $9 | $7.15 | +25.87% | 2 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $420 → $350 | $313.74 | +11.56% | 1 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $16 | $12.13 | +31.90% | 9 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $35 | $20.12 | +73.96% | 4 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $160 → $150 | $115.55 | +29.81% | 21 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $225 → $200 | $81.57 | +145.19% | 16 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $11 | $2.12 | +418.87% | 6 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $70 | $157.29 | -55.50% | 7 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $75 → $90 | $53.40 | +68.54% | 9 | Aug 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $7 | $9.51 | -26.39% | 2 | Feb 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $345 | $366.67 | -5.91% | 12 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $260 | $140.22 | +85.42% | 5 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $160 → $145 | $175.90 | -17.57% | 10 | Feb 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $95 → $90 | $58.81 | +53.04% | 12 | Feb 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $62 → $64 | $42.96 | +48.16% | 3 | Dec 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $330 → $340 | $250.94 | +35.49% | 11 | Dec 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $24 | $23.66 | +1.44% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1,350 → $1,500 | $1,174.59 | +27.70% | 8 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $45 → $35 | $4.25 | +723.53% | 12 | Aug 14, 2019 |
Bio-Techne
May 9, 2025
Maintains: Buy
Price Target: $95 → $70
Current: $53.90
Upside: +29.87%
Bruker
May 8, 2025
Maintains: Neutral
Price Target: $57 → $45
Current: $40.26
Upside: +11.77%
IQVIA Holdings
May 7, 2025
Maintains: Buy
Price Target: $255 → $185
Current: $156.13
Upside: +18.49%
Bio-Rad Laboratories
May 2, 2025
Maintains: Buy
Price Target: $355 → $310
Current: $256.68
Upside: +20.77%
Bio-Rad Laboratories
May 2, 2025
Maintains: Buy
Price Target: $355 → $310
Current: $252.64
Upside: +22.71%
Guardant Health
May 1, 2025
Maintains: Buy
Price Target: $65 → $70
Current: $41.66
Upside: +68.03%
Revvity
May 1, 2025
Upgrades: Buy
Price Target: $145 → $115
Current: $98.50
Upside: +16.75%
Thermo Fisher Scientific
Apr 24, 2025
Maintains: Buy
Price Target: $715 → $500
Current: $432.59
Upside: +15.58%
Danaher
Apr 23, 2025
Maintains: Buy
Price Target: $275 → $240
Current: $200.83
Upside: +19.50%
10x Genomics
Feb 13, 2025
Maintains: Neutral
Price Target: $20 → $14
Current: $9.49
Upside: +47.52%
Jan 17, 2025
Downgrades: Neutral
Price Target: $29 → $25
Current: $13.00
Upside: +92.31%
Jan 17, 2025
Downgrades: Neutral
Price Target: $250 → $185
Current: $143.08
Upside: +29.30%
Oct 18, 2024
Maintains: Neutral
Price Target: $7 → $9
Current: $7.15
Upside: +25.87%
Sep 27, 2024
Downgrades: Neutral
Price Target: $420 → $350
Current: $313.74
Upside: +11.56%
Sep 27, 2024
Upgrades: Buy
Price Target: $16
Current: $12.13
Upside: +31.90%
Dec 7, 2023
Initiates: Neutral
Price Target: $35
Current: $20.12
Upside: +73.96%
Aug 16, 2023
Maintains: Outperform
Price Target: $160 → $150
Current: $115.55
Upside: +29.81%
Aug 10, 2023
Maintains: Neutral
Price Target: $225 → $200
Current: $81.57
Upside: +145.19%
Aug 8, 2023
Maintains: Neutral
Price Target: $14 → $11
Current: $2.12
Upside: +418.87%
Aug 4, 2023
Reiterates: Outperform
Price Target: $70
Current: $157.29
Upside: -55.50%
Aug 2, 2023
Maintains: Neutral
Price Target: $75 → $90
Current: $53.40
Upside: +68.54%
Feb 15, 2023
Reiterates: Underperform
Price Target: $7
Current: $9.51
Upside: -26.39%
Aug 25, 2022
Initiates: Neutral
Price Target: $345
Current: $366.67
Upside: -5.91%
Aug 25, 2022
Initiates: Neutral
Price Target: $260
Current: $140.22
Upside: +85.42%
Feb 4, 2022
Maintains: Equal-Weight
Price Target: $160 → $145
Current: $175.90
Upside: -17.57%
Feb 3, 2022
Maintains: Overweight
Price Target: $95 → $90
Current: $58.81
Upside: +53.04%
Dec 14, 2021
Maintains: Equal-Weight
Price Target: $62 → $64
Current: $42.96
Upside: +48.16%
Dec 14, 2021
Maintains: Overweight
Price Target: $330 → $340
Current: $250.94
Upside: +35.49%
Aug 10, 2021
Initiates: Overweight
Price Target: $24
Current: $23.66
Upside: +1.44%
Jul 30, 2021
Maintains: Equal-Weight
Price Target: $1,350 → $1,500
Current: $1,174.59
Upside: +27.70%
Aug 14, 2019
Maintains: Hold
Price Target: $45 → $35
Current: $4.25
Upside: +723.53%